Rezolute to Participate in the BTIG Virtual Biotechnology Conference
Rezolute (NASDAQ:RZLT), a late-stage rare disease company specializing in hypoglycemia treatment caused by hyperinsulinism, has announced its participation in the upcoming BTIG Virtual Biotechnology Conference scheduled for July 29-30, 2025.
The company's management team will be available for one-on-one meetings with investors during the conference. Interested investors should coordinate with their BTIG representatives to schedule meetings.
Rezolute (NASDAQ:RZLT), un'azienda in fase avanzata specializzata nelle malattie rare e nel trattamento dell'ipoglicemia causata da iperinsulinismo, ha annunciato la sua partecipazione alla prossima Conferenza Virtuale di Biotecnologie BTIG prevista per il 29-30 luglio 2025.
Il team dirigenziale dell'azienda sarà disponibile per incontri individuali con gli investitori durante la conferenza. Gli investitori interessati devono coordinarsi con i loro rappresentanti BTIG per fissare gli appuntamenti.
Rezolute (NASDAQ:RZLT), una empresa en etapa avanzada especializada en enfermedades raras y en el tratamiento de la hipoglucemia causada por hiperinsulinismo, ha anunciado su participación en la próxima Conferencia Virtual de Biotecnología BTIG programada para el 29-30 de julio de 2025.
El equipo directivo de la empresa estará disponible para reuniones individuales con inversores durante la conferencia. Los inversores interesados deben coordinar con sus representantes de BTIG para agendar las reuniones.
Rezolute (NASDAQ:RZLT)는 희귀질환 중 후기 단계에 있는 회사로, 고인슐린혈증에 의한 저혈당 치료를 전문으로 하며, 2025년 7월 29일~30일에 예정된 BTIG 가상 바이오테크 컨퍼런스에 참가한다고 발표했습니다.
회사의 경영진은 컨퍼런스 기간 동안 투자자들과 일대일 미팅을 진행할 예정입니다. 관심 있는 투자자들은 BTIG 담당자와 연락하여 미팅 일정을 조율해야 합니다.
Rezolute (NASDAQ:RZLT), une entreprise en phase avancée spécialisée dans les maladies rares et le traitement de l’hypoglycémie causée par l’hyperinsulinisme, a annoncé sa participation à la prochaine Conférence virtuelle BTIG sur la biotechnologie prévue les 29 et 30 juillet 2025.
L’équipe de direction sera disponible pour des rencontres individuelles avec les investisseurs durant la conférence. Les investisseurs intéressés doivent coordonner avec leurs représentants BTIG pour organiser ces rendez-vous.
Rezolute (NASDAQ:RZLT), ein Unternehmen in der späten Entwicklungsphase, das sich auf seltene Krankheiten und die Behandlung von Hypoglykämie durch Hyperinsulinismus spezialisiert hat, hat seine Teilnahme an der kommenden BTIG Virtuellen Biotechnologie-Konferenz angekündigt, die für den 29.-30. Juli 2025 geplant ist.
Das Management-Team des Unternehmens steht während der Konferenz für Einzelgespräche mit Investoren zur Verfügung. Interessierte Investoren sollten sich mit ihren BTIG-Ansprechpartnern abstimmen, um Termine zu vereinbaren.
- None.
- None.
REDWOOD CITY, Calif., July 22, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism, today announced that management will participate in the BTIG Virtual Biotechnology Conference, taking place July 29-30, 2025.
Management will be participating in one-on-one investor meetings throughout the conference. Investors interested in scheduling a meeting with the Rezolute management team should contact their BTIG representative.
About Rezolute, Inc.
Rezolute is a late-stage rare disease company focused on significantly improving outcomes for individuals with hypoglycemia caused by hyperinsulinism (“HI”). The Company’s antibody therapy, ersodetug, is designed to treat all forms of HI and has shown substantial benefit in clinical trials and real-world use for the treatment of congenital HI and tumor HI. For more information, visit www.rezolutebio.com.
Contact:
Rezolute, Inc.
Christen Baglaneas
cbaglaneas@rezolutebio.com
508-272-6717
Media
Sarah Lima
Sarah@GalvinPR.com
(774) 766-0200
FAQ
When is Rezolute (RZLT) participating in the BTIG Virtual Biotechnology Conference 2025?
How can investors meet with Rezolute (RZLT) management at the BTIG conference?
What is Rezolute's (RZLT) main focus as a company?
What type of meetings will Rezolute (RZLT) management conduct at the BTIG conference?
